108 related articles for article (PubMed ID: 30668187)
1. The potential health gain and cost savings of improving adherence in chronic myeloid leukemia.
Ector GICG; Govers TM; Westerweel PE; Grutters JPC; Blijlevens NMA
Leuk Lymphoma; 2019 Jun; 60(6):1485-1492. PubMed ID: 30668187
[TBL] [Abstract][Full Text] [Related]
2. Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands.
Ector GICG; Geelen IGP; Dinmohamed AG; Hoogendoorn M; Westerweel PE; Hermens RPMG; Blijlevens NMA
Leuk Lymphoma; 2023 Feb; 64(2):424-432. PubMed ID: 36369821
[TBL] [Abstract][Full Text] [Related]
3. Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007.
Lin PJ; Winn AN; Parsons SK; Neumann PJ; Weiss ES; Cohen JT
Med Care; 2016 Apr; 54(4):380-5. PubMed ID: 26759984
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
5. Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.
Maheshwari VK; Slader C; Dani N; Gkitzia C; Yuan Q; Xiong T; Liu Y; Viana R
PLoS One; 2021; 16(10):e0259076. PubMed ID: 34695169
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
7. Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2018 Oct; 21(10):1036-1040. PubMed ID: 30071761
[TBL] [Abstract][Full Text] [Related]
8. Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia.
Gater A; Heron L; Abetz-Webb L; Coombs J; Simmons J; Guilhot F; Rea D
Leuk Res; 2012 Jul; 36(7):817-25. PubMed ID: 22364811
[TBL] [Abstract][Full Text] [Related]
9. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
[TBL] [Abstract][Full Text] [Related]
10. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
11. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia.
Goldberg SL; Akard LP; Dugan MJ; Faderl S; Pecora AL
J Oncol Pract; 2015 May; 11(3):e398-404. PubMed ID: 25758446
[TBL] [Abstract][Full Text] [Related]
12. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Warren E; Ward S; Gordois A; Scuffham P
Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
[TBL] [Abstract][Full Text] [Related]
14. Failure mode and effects analysis of medication adherence in patients with chronic myeloid leukemia.
Hosoya K; Mochinaga S; Emoto A; Yokoo H; Tokushima H; Egoshi M; Sueoka-Aragane N; Kimura S
Int J Clin Oncol; 2015 Dec; 20(6):1203-10. PubMed ID: 26002407
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
16. Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
Jabbour EJ; Siegartel LR; Lin J; Lingohr-Smith M; Menges B; Makenbaeva D
Leuk Lymphoma; 2019 Mar; 60(3):668-674. PubMed ID: 30124372
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Unnikrishnan R; Veeraiah S; Mani S; Rajendranath R; Rajaraman S; Vidhubala Elangovan GS; Radhakrishnan V; Ganesan TS; Sagar TG; Ganesan P
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):366-371.e3. PubMed ID: 27052853
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation.
McGrady ME; Eckman MH; O'Brien MM; Pai ALH
J Pediatr Psychol; 2018 Aug; 43(7):758-768. PubMed ID: 29771338
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]